Meeting
2014 ASCO Annual Meeting
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
Authors
Neil Howard Segal
Memorial Sloan-Kettering Cancer Center, New York, NY
Neil Howard Segal , F. Stephen Hodi , Rachel E. Sanborn , Thomas Gajewski , Jedd D. Wolchok , Walter John Urba , Bernard A. Fox , Suzanne Louise Topalian , Drew M. Pardoll , Georgia Kollia , Dan McDonald , Su Young Kim , William Howard Sharfman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01714739
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3115)
DOI
10.1200/jco.2014.32.15_suppl.tps3115
Abstract #
TPS3115
Poster Bd #
180A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.
First Author: Rachel E. Sanborn
Poster
2022 ASCO Annual Meeting
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.
First Author: Gerald Steven Falchook
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2016 ASCO Annual Meeting
A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.
First Author: Aung Naing